Back to Search Start Over

Probable Miglustat-Induced Psychosis in a Child With Niemann-Pick Type C.

Authors :
Koç Yekedüz M
Öncül Ü
Köse E
Eminoğlu FT
Source :
Clinical neuropharmacology [Clin Neuropharmacol] 2022 Jul-Aug 01; Vol. 45 (4), pp. 107-109. Date of Electronic Publication: 2022 Jun 11.
Publication Year :
2022

Abstract

Background: Niemann-Pick disease type C (NP-C) is a neurodegenerative lysosomal disease in which psychiatric symptoms, such as psychosis, can also be observed. Miglustat is indicated in cases with progressive neurological manifestations, and although there have been studies reporting that miglustat completely cures psychosis, it has been recently observed that miglustat may also trigger psychosis. We report on a rare case of probable miglustat-induced psychosis in a patient with NP-C.<br />Case: A 21-year-old female patient presented with a complaint of social isolation that started at the age of 6 years. During clinical follow-up, the patient's clinical progress deteriorated, and ocular apraxia, ataxia, seizures, and dementia developed at the age of 15 years. A genetic investigation was performed, and a homozygous p.P120S (c.358C > T) variant was detected in the NPC2 gene. Miglustat was initiated at the age of 15 years, and during the 6 months of treatment, psychotic symptoms such as unwarranted anger, suspiciousness, and delusions developed. Consequently, the miglustat was discontinued by the parents of the patient, and the psychosis completely disappeared. The patient has experienced no further psychotic episodes in the approximately 5.5 years following the discontinuation of therapy.<br />Conclusion: Although a positive effect of miglustat on neurological and psychiatric symptoms has been reported, there exists a risk of psychosis being triggered. To the best of our knowledge, this is the first case of pediatric NP-C to develop psychosis after miglustat to be reported in literature. Further studies of such cases are needed to understand the impact of miglustat on psychiatric symptoms in NP-C.<br />Competing Interests: Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare.<br /> (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)

Details

Language :
English
ISSN :
1537-162X
Volume :
45
Issue :
4
Database :
MEDLINE
Journal :
Clinical neuropharmacology
Publication Type :
Academic Journal
Accession number :
35696615
Full Text :
https://doi.org/10.1097/WNF.0000000000000511